Riverine Ventures

Garrett Vygantas leads the firm as Founder & Managing Partner, drawing on his medical degree from Georgetown and operating experience at Genentech. Scott Robert Lancaster, a board-certified diagnostic radiologist and former clinical director of Spectrum Health Ventures, works alongside him on investment execution. The partnership model places investment authority with practicing clinicians rather than career financiers.

Riverine concentrates on early-stage private companies through its flagship P9 venture strategy. Its representative holdings span seed to Series B-stage biomedical startups, including Inflammatix and CellFE. The firm works closely with management teams post-investment to reach commercial milestones with capital efficiency.

Riverine executes primarily through direct equity investments rather than acting as a fund-of-funds. The firm takes board seats or active advisory roles in portfolio companies. Its capital base is structured via The 4100 Group's permanent capital vehicle, which supports a longer hold period than traditional fund commitments.

Both Garrett Vygantas and Scott Robert Lancaster previously invested on behalf of The 4100 Group, a permanent capital vehicle. Riverine Ventures leverages that relationship as a source of anchor funding, which influences the firm's flexible investment horizon and governance model aligned with patient, rather than institutional, capital.

Riverine's published materials and portfolio point to an exclusive focus on life sciences and healthcare, with no disclosed exposure to consumer internet, enterprise SaaS outside of health verticals, financial technology, or climate tech. The partnership's clinical backgrounds anchor the firm to biomedical risk that they are professionally trained to evaluate.

Individual partners have extensive non-profit involvement—Scott Lancaster and his wife lead initiatives with the Grand Rapids Children's Museum and Make-A-Wish in West Michigan—but there is no indication these are coordinated through a dedicated Riverine philanthropic vehicle. Philanthropic activity appears personally managed by partners rather than integrated into the firm's investment operations.

Riverine's website highlights its network-driven sourcing model and notes partnerships with entrepreneur-investors, but does not publish a formal co-investment policy. Prior affiliations with institutional platforms like Burrill & Co. and OSF Healthcare suggest comfort with syndicates; the firm's board-heavy post-investment approach signals a preference for lead or co-lead roles where clinical expertise is additive, rather than passive LP participation.